Pfizer, Kintor in deal for ACVRL1 mab

Pfizer Inc. (NYSE:PFE) granted Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) exclusive, worldwide rights to develop and commercialize PF-03446962 (PF-3446962), a human mAb against activin receptor-like kinase 1 (ACVRL1; ALK1; HHT2). Pfizer may opt to obtain ex-Chinese rights.

Two Phase I trials showed that PF-03446962 was safe in patients with advanced solid tumors and led to some disease control in liver cancer patients. Kintor will conduct global Phase II trials of the candidate to treat liver cancer and also plans to test PF-03446962 in combination therapies and explore its use in other indications. The company will also transfer production of the candidate to China...